Search Result

Results for "

GLP-1 agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLP Receptor (51) Akt (1) Cytochrome P450 (2) Free Fatty Acid Receptor (5) G protein-coupled Bile Acid Receptor 1 (1) G Protein-coupled Receptor Kinase (GRK) (1) GCGR (61) GPR119 (2) Insulin Receptor (3) Isotope-Labeled Compounds (2) JNK (1) MEK (1) MMP (1) TRP Channel (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (4) Inflammation/Immunology (3) Metabolic Disease (99) Neurological Disease (6)

115

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: GLP Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153798

GLP-1 receptor agonist 10	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 10 (compound 42) is an agonist of GLP Receptor. GLP-1 receptor agonist 10 inhibits food intake and reduces glucose excursion in mice. GLP-1 receptor agonist 10 can be used in the study of type 2 diabetes (T2DM) and obesity .

HY-145412

GLP-1 receptor agonist 7	GCGR	Metabolic Disease
GLP-1 receptor agonist 7 is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 has the potential for the research of GLP-1-associated diseases, disorders, and conditions including diabetes mellitus (extracted from patent WO2021219019A1, compound 130b) .

HY-153815

GLP-1 receptor agonist 11	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 11 (compound 3) is an agonist of GLP Receptor. GLP-1 receptor agonist 11 can be used in the study of diseases such as diabetes and non-alc. fatty liver disease .

HY-112679

GLP-1 receptor agonist 2	GCGR	Others
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor *(GLP-1R)* agonist.

HY-156968

GLP-1 receptor agonist 14	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 14 (compound 73) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders .

HY-155147

GLP-1 receptor agonist 13	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 13 (compound (S)-9) is a glucagon GLP-1 receptor agonist with EC₅₀ of 76 nM .

HY-153816

GLP-1 receptor agonist 12	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 12 (compound 20A) is an agonist of GLP Receptor. GLP-1 receptor agonist 12 can be used in the study of diseases such as diabetes .

HY-145458

GLP-1 receptor agonist 9	GCGR	Metabolic Disease
GLP-1 receptor agonist 9 is a GLP-1 receptor agonist, example 7, extracted from WO2020234726 A1 .

HY-138996

GLP-1 receptor agonist 8	GCGR	Metabolic Disease
GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17) .

HY-129657

GLP-1 receptor agonist 4	GCGR	Metabolic Disease
GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC₅₀ of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes .

HY-129656

GLP-1 receptor agonist 3	GCGR	Metabolic Disease
GLP-1 receptor agonist 3 (compound (R)-4A-1) is a GLP-1 receptor agonist (WO2018109607A1), used for diabetes research. compound (S)-4A-1 shows EC₅₀s of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell lines assay, respectively .

HY-112185A

Orforglipron hemicalcium hydrate 1 Publications Verification LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate	GCGR	Metabolic Disease
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .

HY-148212

GLP-1R agonist 17	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1R agonist 17 is a GLP-1 receptor agonist. GLP-1R agonist 17 shows excellent agonism on a GLP-1 receptor. GLP-1R agonist 17 can be used for the research of cardiovascular metabolic diseases .

HY-112185

Orforglipron 1 Publications Verification LY3502970; GLP-1 receptor agonist 1	GCGR	Metabolic Disease
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .

HY-147626

GLP-1R agonist 13	GLP Receptor	Metabolic Disease
GLP-1R agonist 13 (Compound 24) is a GLP-1 receptor agonist .

HY-147628

GLP-1R agonist 15	GLP Receptor	Metabolic Disease
GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist .

HY-147623

GLP-1R agonist 10	GLP Receptor	Metabolic Disease
GLP-1R agonist 10 (Compound 109a) is a *GLP-1* agonist with an EC₅₀ of 0.051 nM .

HY-147629

GLP-1R agonist 16	GLP Receptor	Metabolic Disease
GLP-1R agonist 16 (Compound 115a) is a GLP-1 receptor agonist with an EC₅₀ of 0.15 nM .

HY-147627

GLP-1R agonist 14	GLP Receptor	Metabolic Disease
GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC₅₀ of 0-20 nM against h-GLP-1 .

HY-162979

GLP-1R agonist 25	GLP Receptor	Metabolic Disease
GLP-1R agonist 25 (compound 13) is a *GLP1-R* agonist, with an EC₅₀ of 0.167 nM. GLP-1R agonist 25 can be used in type II diabetes research .

HY-162435

GLP-1R agonist 20	GLP Receptor	Metabolic Disease
GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0162 nM .

HY-162436

GLP-1R agonist 21	GLP Receptor	Metabolic Disease
GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0104 nM .

HY-162437

GLP-1R agonist 22	GLP Receptor	Metabolic Disease
GLP-1R agonist 22 (Compound I-135) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0165 nM .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for *GLP-1* (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones *GLP-1* and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-153816A

*(1R)-GLP-1* receptor agonist 12**	Others	Others
(1R)-GLP-1 receptor agonist 12 is the isomer of GLP-1 receptor agonist 12 (HY-153816) .

HY-164774

*(4S)-GLP-1* receptor agonist 14**	GLP Receptor	Metabolic Disease
(4S)-GLP-1 receptor agonist 14 (Compound 73) is a *GLP-1* receptor modulator .

HY-144035

GLP-1R agonist 4	GCGR	Cancer
GLP-1R agonist 4 is a potent agonist of *GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist* 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96) .

HY-144034

GLP-1R agonist 3	GCGR	Metabolic Disease
GLP-1R agonist 3 is a potent agonist of *GLP-1R. GLP-1R agonist* 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .

HY-144033

GLP-1R agonist 1	GCGR	Metabolic Disease
GLP-1R agonist 1 is a potent agonist of *GLP-1R. GLP-1R agonist* 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC₅₀ is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC₅₀ is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones *GLP-1* and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-161915

GLP-1R agonist 23	GLP Receptor	Metabolic Disease
GLP-1R agonist 23 (Example 376) is a *GLP-1R* agonist with an EC₅₀ of 0.056 nM. GLP-1R agonist 23 can be used in diabetes research .

HY-147625

GLP-1R agonist 12	GLP Receptor	Metabolic Disease
GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research .

HY-P10327

PP18	GLP Receptor	Metabolic Disease
PP18 is a novel OXM-based dual *GLP-1* and glucagon receptor agonist with EC₅₀ values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .

HY-160031

GLP-1R agonist 19	GLP Receptor	Cardiovascular Disease
GLP-1R agonist 19 (M3190) is a potent and selective *GLP-1R* agonist. GLP-1R agonist 19 has excellent plasma stability, liver microsomal stability, and low hERG toxicity .

HY-162306

GLP-1R agonist 18	GLP Receptor	Cancer
GLP-1R agonist 18 (example 117) is an agonist for *GLP-1R* with an EC₅₀ of 0.044 nM .

HY-144136

GLP-1R agonist 8	GCGR	Metabolic Disease
GLP-1R agonist 8 is a potent *GLP-1R* agonist with an EC₅₀ of < 2 nM (WO2021219019A1, compound 129a) .

HY-144133

GLP-1R agonist 5	GCGR	Metabolic Disease
GLP-1R agonist 5 is a potent *GLP-1R* agonist with an EC₅₀ of <10 nM (WO2021259309A1, compound 35) .

HY-144134

GLP-1R agonist 6	GCGR	Metabolic Disease
GLP-1R agonist 6 is a potent *GLP-1R* agonist with an EC₅₀ of 0.15 nM for human GLP-1R (WO2021249492A1, compound 005A or 005B) .

HY-147622

GLP-1R agonist 9	GCGR	Metabolic Disease
GLP-1R agonist 9 (Compound 96) is a *GLP-1R* agonist with EC₅₀ values of 1.1 nM and 11 nM against CHO GLP-1R Clone H6 and CHO GLP-1R Clone C6, respectively .

HY-121835

GLP-1R agonist 2	GCGR	Metabolic Disease
GLP-1R agonist 2 (compound 2) is an effective *GLP-1R* agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of *GLP-1R. GLP-1R agonist* 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity .

HY-168585

GLP-1R agonist 26	GLP Receptor	Metabolic Disease
GLP-1R agonist 26 (compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC₅₀ of <10 nM .

HY-144135

GLP-1R agonist 7	GCGR	Metabolic Disease
GLP-1R agonist 7 is a potent *GLP-1R* agonist with an EC₅₀ of 0.67 µM (WO2021244645A1, compound WXA001) .

HY-153476

*GIP/GLP-1* dual receptor agonist-1**	GCGR	Metabolic Disease
GIP/GLP-1 dual receptor agonist-1 (compound 4) is a *GIP/GLP-1* receptor** agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .

HY-114118

Semaglutide 4 Publications Verification	GCGR	Metabolic Disease Cancer
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 *(GLP-1)* receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.

HY-114118B

Semaglutide acetate 4 Publications Verification	GCGR	Metabolic Disease
Semaglutide acetate, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 *(GLP-1)* receptor agonist. Semaglutide acetate has the potential for type 2 diabetes treatment.

HY-103546

BETP 1 Publications Verification	GCGR	Metabolic Disease
BETP is an agonist of *glucagon-like peptide-1 (GLP-1) receptor, with EC₅₀s of 0.66 and 0.755 μM for human and rat GLP-1* receptor, respectively.

HY-114118A

Semaglutide TFA 4 Publications Verification	GCGR	Metabolic Disease Cancer
Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 *(GLP-1)* receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.

HY-P10592

Bofanglutide	GLP Receptor	Metabolic Disease
Bofanglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P1348

GLP-1 moiety from Dulaglutide	GCGR	Metabolic Disease
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.

HY-114118F

Semaglutide, FITC labeled	GCGR	Metabolic Disease
Semaglutide, FITC labeled is a FITC labeled Semaglutide. Semaglutide, a long-acting *GLP-1* alogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment .

Cat. No.	Product Name	Type

HY-114118F

Semaglutide, FITC labeled	Fluorescent Dyes/Probes
Semaglutide, FITC labeled is a FITC labeled Semaglutide. Semaglutide, a long-acting *GLP-1* alogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment .

Cat. No.	Product Name	Target	Research Area

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC₅₀ is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC₅₀ is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones *GLP-1* and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-114118

Semaglutide 4 Publications Verification	GCGR	Metabolic Disease Cancer
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 *(GLP-1)* receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.

HY-114118B

Semaglutide acetate 4 Publications Verification	GCGR	Metabolic Disease
Semaglutide acetate, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 *(GLP-1)* receptor agonist. Semaglutide acetate has the potential for type 2 diabetes treatment.

HY-114118A

Semaglutide TFA 4 Publications Verification	GCGR	Metabolic Disease Cancer
Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 *(GLP-1)* receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.

HY-P1348

GLP-1 moiety from Dulaglutide	GCGR	Metabolic Disease
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.

HY-114118F

Semaglutide, FITC labeled	GCGR	Metabolic Disease
Semaglutide, FITC labeled is a FITC labeled Semaglutide. Semaglutide, a long-acting *GLP-1* alogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for *GLP-1* (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones *GLP-1* and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P10327

PP18	GLP Receptor	Metabolic Disease
PP18 is a novel OXM-based dual *GLP-1* and glucagon receptor agonist with EC₅₀ values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .

HY-P10592

Bofanglutide	GLP Receptor	Metabolic Disease
Bofanglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P1145

Glucagon-like peptide 1 (1-37), human HuGLP-1	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

HY-108795A

Albiglutide fragment TFA GLP-1-Gly8 TFA; GLP-1 (7-36) analog TFA	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting *GLP-1* receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .

HY-108795

Albiglutide fragment GLP-1-Gly8; GLP-1 (7-36) analog	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting *GLP-1* receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .

HY-P1145A

Glucagon-like peptide 1 (1-37), human TFA 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P5311

Albiglutide	GLP Receptor	Metabolic Disease
Albiglutide is a long acting GLP-1 receptor agonist. Albiglutide can be used for research of Type 2 diabetes .

HY-P0014

Liraglutide Maximum Cited Publications 22 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P1144

Oxyntomodulin (bovine, porcine) Glucagon-37 (bovine, porcine)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P1144A

Oxyntomodulin (bovine, porcine) (TFA) Glucagon-37 (bovine, porcine) (TFA)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine) TFA, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P10736

AMG133 peptide payload	GCGR	Metabolic Disease
AMG133 peptide payload is a *GLP-1* agonist that can be used as a peptide linker conjugate of AMG133 (HY-164535) .

HY-P3491

Pegloxenatide PEX 168	GLP Receptor	Metabolic Disease
Pegloxenatide is a *glucagon-like peptide-1 receptor (GLP-1* RA)** agonist. Pegloxenatide can be used for type 2 diabetes research .

HY-P10591

Olatorepatide Olatorepatidum	Insulin Receptor GLP Receptor	Metabolic Disease
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .

HY-P0165

Taspoglutide ITM077; R1583; BIM51077	GCGR	Metabolic Disease
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC₅₀ value of 0.06 nM.

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GCGR	Metabolic Disease
Lixisenatide acetate is a *glucagon-like peptide-1 (GLP-1) receptor* agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the *GLP-1* receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P10312

SPN009	GLP Receptor	Metabolic Disease
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC₅₀ of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .

HY-P3366

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 *(GLP-1) receptor* agonist. Ecnoglutide can be used for research of T2DM and obesity .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵N (TFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-P0014S1

Liraglutide-13C5,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₅, ¹⁵N (tetraTFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-P0119

Lixisenatide 2 Publications Verification	GCGR MEK Akt MMP JNK	Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^−/− Irs ^2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P3255

DA-JC4	Insulin Receptor	Neurological Disease Inflammation/Immunology
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways .

HY-P4386

(Asp28)-Exenatide	GLP Receptor	Metabolic Disease
(Asp28)-Exenatide is a degradation product of exenatide (HY-13443). (Asp28)-Exenatide can be used as a *GLP-1R* agonist .

HY-P3506

Retatrutide 1 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P3506A

Retatrutide TFA 1 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P10716

Exendin-P5	GLP Receptor	Metabolic Disease
Exendin-P5 is a selective agonist that targets the *GLP-1R. Exendin-P5 promotes rapid activation of G proteins by transient interactions with the transmembrane domain of GLP-1R, enhancing its potency in G protein*-mediated signaling and accelerating cAMP production. This mechanism suggests the potential application of Exendin-P5 in the study of metabolic diseases .

HY-P5161A

FC382K10W15 TFA	GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and *GLP-1R/GCGR* agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P10032A

NN1177 TFA NNC9204-1177 TFA	GCGR Cytochrome P450 GLP Receptor	Metabolic Disease
NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease
Pegsebrenatide (NLY01) is a long-acting *GLP-1R* agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of *GLP-1R* (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P3539

Exendin-4 (3-39)	GCGR	Neurological Disease Endocrinology
Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0630

Shanzhiside methyl ester	Structural Classification Iridoids Terpenoids Labiatae Phaseolus lunatus L. Source classification Plants	GCGR
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule *glucagon-like peptide-1 (GLP-1) receptor* agonist and has the ability to induce anti-allodynic tolerance .

HY-W011121

2-Oleoylglycerol	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	GPR119
2-Oleoylglycerol is a dietary naturally occurring lipid. 2-Oleoylglycerol is a GPR119 agonist, with an EC₅₀ of 2.5 μM for human GPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol stimulates glucagon-like peptide-1 (GLP-1) secretion in vivo .

HY-N2452

Cochinchinenin C	other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	GCGR
Cochinchinenin C is a nonpolypeptide agonist of *glucagon-like peptide-1 (GLP-1) receptor*. Cochinchinenin C can be used for the research of diabetes .

HY-N0630R

Shanzhiside methyl ester (Standard)	Structural Classification Iridoids Terpenoids Labiatae Phaseolus lunatus L. Source classification Plants	GCGR
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .

HY-113513

5-HEPE	Microorganisms Source classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Cat. No.	Product Name	Chemical Structure

HY-P0014S1

Liraglutide-13C5,15N TFA
Liraglutide- ¹³C₅, ¹⁵N (tetraTFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵N (TFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

GLP-1 agonist

Inhibitors & Agonists

Fluorescent Dye

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products